A direct, selective factor Xa inhibitor for:

• Prevention of stroke in patients with atrial fibrillation.
• Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).
• Prevention of venous thromboembolism (VTE) following knee or hip replacement.
• Rapid onset of action.
• Predictable anticoagulant effect.
• Low potential for food and drug interactions.
• Laboratory monitoring is not required.
• Simple, effective, and safe dosage regimen for the initial and long-term use.
• Low risk of major bleeding (including GI bleeding) in all age groups.
• Safer than other oral anticoagulant agents in patients with renal insufficiency.
• Suitable for atrial fibrilation patients who are not candidates for vitamin K antagonist therapy.